This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

Clinical Trials

Our clinical studies are designed to characterize the safety, pharmacology, biological activity, and clinical potential of our investigational NLRP3 inhibitors.

Clinical Program
Program:
Ruvonoflast
Study Name:
RESOLVE-1
Phase:
Phase 2a
Status:
Completed
Trial Overview

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 24 week treatment period.

For more information, please visit clinicaltrials.gov (NCT07055516).

Clinical Program
Program:
Ruvonoflast
Study Name:
RESOLVE-2
Phase:
Phase 2a
Status:
Not Recruiting
Trial Overview

A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 32 week treatment period.

For more information, please visit clinicaltrials.gov (NCT07220629).

Clinical Program
Program:
Trabzanoflast
Study Name:
First in Human
Phase:
Phase 1
Status:
Completed
Trial Overview

A study investigating the safety, absorption, and elimination of NT-0150, a new compound that may potentially be used in the treatment of brain disorders.

For more information, please visit NL-OMON60655.

See Our Development Pipeline